
ACADIA Pharma (ACAD) Stock Forecast & Price Target
ACADIA Pharma (ACAD) Analyst Ratings
Bulls say
ACADIA Pharmaceuticals is poised for success due to its strong commercial execution with NUPLAZID and DAYBUE, as shown by the positive fourth quarter results and optimistic 2026 guidance. Furthermore, the company has a diverse pipeline with potential in various neurological and rare diseases, including Alzheimer's and Lewy body dementia. With a strong focus on diversity and inclusion, ACADIA demonstrates a commitment to a talented workforce and is well-positioned for continued growth in the future.
Bears say
ACADIA Pharmaceuticals is facing multiple risks in the form of lower estimates for Daybue, potential dilutive equity offerings, and challenges in expanding to new indications with their current therapeutic mechanisms. Though they have seen some success with NUPLAZID and DAYBUE, their clinical-stage developments and upcoming regulatory decisions are a key factor in our negative outlook on the stock. Additionally, a recent negative trend vote from the European Medicines Agency for a key drug in their pipeline could delay potential revenue opportunities. Overall, we believe the company is overvalued and poses a high level of risk.
This aggregate rating is based on analysts' research of ACADIA Pharma and is not a guaranteed prediction by Public.com or investment advice.
ACADIA Pharma (ACAD) Analyst Forecast & Price Prediction
Start investing in ACADIA Pharma (ACAD)
Order type
Buy in
Order amount
Est. shares
0 shares